Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Consulting agrmnt
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update • CRB-701 Phase 1 trial in China is ahead of schedule with dose escalation completion expected Q4 2023 and U.S. clinical trial start planned for Q1 2024 • Preliminary clinical PK data indicates CRB-701 has a longer half-life and reduced levels of circulating free MMAE relative to published data for PADCEV® • CRB-601 IND submission is on track for Q4 2023 Norwood, MA, August 8, 2023 -- Corbus Pharmaceuticals Holdings, Inc. , a precision oncology company, today provided a corporate update and reported financial results for the second quarter of 2023. “During the second quarter, substantial progress was made advancing CRB-701, our next generation Nectin-4 antibody dru..."
08/03/2023 8-K Investor presentation
Docs: "2019. 2. 2022 ESMO, LBA73"
05/19/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/09/2023 8-K Quarterly results
Docs: "Corbus Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update • Company expanded precision oncology pipeline with in-licensing of CRB-701: a clinical-stage Nectin-4 antibody drug conjugate from CSPC Pharmaceutical Group • CRB-701 Phase 1 dose escalation study ongoing in patients with advanced solid tumors in China • Presented latest CRB-601 anti-αvβ8 mAb pre-clinical data at American Association of Cancer Research 2023 annual meeting with IND submission on track for the second half of 2023 • Expanded Board of Directors with appointment of Yong Ben, MD Norwood, MA, May 9, 2023 -- Corbus Pharmaceuticals Holdings, Inc. , a precision oncology company, today provided a corporate update and reported financial results for..."
03/07/2023 8-K Investor presentation, Quarterly results
Docs: "Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update • Company expands precision oncology pipeline with licensing of CRB-701, clinical-stage Nectin-4 antibody drug conjugate from CSPC Pharmaceutical Group • CRB-701 Phase 1 dose escalation ongoing in China in patients with advanced solid tumors • CRB-601 anti-αvβ8 mAb program scheduled for IND submission in the second half of 2023 • CRB-601 continues to demonstrate compelling pre-clinical monotherapy and combination data with anti-PD-1 • Dr. Yong Ben, distinguished oncology researcher joins the Corbus Board of Directors Norwood, MA, March 7, 2023 -- Corbus Pharmaceuticals Holdings, Inc. , a precision oncology company, today provided a c...",
"BT8009 MOA ADC ADC BTC"
03/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA Norwood, MA, March 6, 2023"
02/13/2023 8-K Quarterly results
01/06/2023 8-K Quarterly results
12/21/2022 8-K Quarterly results
12/21/2022 8-K Quarterly results
10/31/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT entered into as of October 25, 2022, by and among Corbus Pharmaceuticals, Inc., a Delaware corporation , and each other Person party thereto as a borrower from time to time , Corbus Pharmaceuticals Holdings, Inc., a Delaware corporation , lenders constituting Required Lenders and K2 HEALTHVENTURES LLC, as administrative agent for Lenders . RECITALS A. The parties hereto previously entered into that certain Loan and Security Agreement, dated as of July 28, 2020 , by and among Borrower Representative, Parent, Lenders, Administrative Agent and Ankura Trust Company, LLC, as collateral agent for Lenders . Capitalized terms used but not defined in this Amendment shall have the respective meanings..."
10/12/2022 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "AMENDMENT NO. 2 TO THE AMENDED AND RESTATED BYLAWS OF CORBUS PHARMACEUTICAL HOLDINGS, INC. Article I of the Amended and Restated Bylaws of Corbus Pharmaceuticals Holdings, Inc., a Delaware corporation, as amended to date , is hereby amended as follows: Article I, Section 5 of the Bylaws be, and hereby is, amended to read in its entirety as follows: “SECTION 5. Quorum. Except as specifically provided otherwise by the DGCL, the Certificate of Incorporation, or these Bylaws, the presence, in person or by proxy, of the holders of one-third in voting power of the shares of capital stock issued and outstanding and entitled to vote at a meeting of stockholders of the issued and outstanding shares of Common Stock of the Corporation entitled to vote at the meeting) shall constitute a quorum ...",
"CORBUS PHARMACEUTICALS HOLDINGS, INC. CERTIFICATE OF DESIGNATION OF SERIES A PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Corbus Pharmaceuticals Holdings, Inc., a Delaware corporation , that the following resolution was duly adopted by the board of directors of the Corporation , in accordance with the provisions of Section 151 of the General Corporation Law of the State of Delaware, as amended , at a meeting duly called and held on October 11, 2022, which resolution provides for the creation of a series of the Corporation’s Preferred Stock, par value $0.0001 per share, which is designated as “Series A Preferred Stock,” with the rights, powers and preferences, and the qualifica..."
09/26/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Corbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of Directors Norwood, MA, September 26, 2022"
08/09/2022 8-K Quarterly results
Docs: "Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update • Promising pre-clinical data generated for CRB-601 across several tumor models as monotherapy and in combination with anti-PD1 therapy • IND submission for CRB-601 is on track for mid-2023 • Expanding immuno-oncology pipeline through strategic transactions remains key priority • Cash and investments on hand of $74 million funds operations into the first quarter of 2024 Norwood, MA, August 9, 2022 -- Corbus Pharmaceuticals Holdings, Inc. , an immunology company, today provided a corporate update and reported financial results for the second quarter of 2022. Key Corporate and Program Updates: • Anti-integrin monoclonal antibody programs targeting the inhibiti..."
07/07/2022 8-K Quarterly results
06/08/2022 8-K Quarterly results
05/23/2022 8-K Quarterly results
05/17/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
04/15/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FOURTH AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Fourth Amended and Restated Employment Agreement , effective as of April 11, 2022 , is between Corbus Pharmaceuticals Holdings, Inc. and Yuval Cohen . WITNESSETH: WHEREAS, the Executive has been employed by the Company as its Chief Executive Officer pursuant to the terms of a third amended and restated employment agreement effective April 11, 2020 ; WHEREAS, the Company desires to continue to employ the Executive as its Chief Executive Officer, and the Executive desires to accept such continued employment, on the terms and conditions set forth in this Agreement; and WHEREAS, the Company and the Executive have mutually agreed that, as of the Effective Date, this Agreement shall amend, restate and replace the Prior Employment Agreement. N...",
"FIFTH AMENDED AND RESTATED EMPLOYMENT AGREEMENT This FIFTH AMENDED AND RESTATED EMPLOYMENT AGREEMENT , effective as of April 11, 2022 , is between Corbus Pharmaceuticals Holdings, Inc. and Sean Moran . WITNESSETH: WHEREAS, the Executive has been employed by the Company as its Chief Financial Officer pursuant to the terms of a fourth amended and restated employment agreement effective April 11, 2020 ; WHEREAS, the Company desires to continue to employ the Executive as its Chief Financial Officer, and the Executive desires to accept such continued employment, on the terms and conditions set forth in this Agreement; and WHEREAS, the Company and the Executive have mutually agreed that, as of the Effective Date, this Agreement shall amend, restate and replace the Prior Employment Agreement. NOW...",
"SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT , effective as of April 11, 2022 , is between Corbus Pharmaceuticals Holdings, Inc. and Craig Millian . WITNESSETH: WHEREAS, the Executive has been employed by the Company as its Chief Operating Officer pursuant to the terms of an amended and restated employment agreement effective April 11, 2020, as amended by an amendment dated as of September 27, 2021 ; WHEREAS, the Company desires to continue to employ the Executive as its Chief Operating Officer, and the Executive desires to accept such continued employment, on the terms and conditions set forth in this Agreement; and WHEREAS, the Company and the Executive have mutually agreed that, as of the Effective Date, this Agreement shall amen..."
04/11/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research Annual Meeting Norwood, MA, April 8, 2022"
03/08/2022 8-K Quarterly results
01/03/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
11/12/2021 8-K Quarterly results
Docs: "Corbus Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Updates  Company continues to advance integrin program from preclinical development toward the clinic  Expanding pipeline through strategic transactions remains key priority  Cash and investments on hand of $108 million sufficient to support execution of research, clinical and operational goals into the first quarter of 2024 Norwood, MA, November 12, 2021 -- Corbus Pharmaceuticals Holdings, Inc. , an immunology company, today provided corporate updates and reported financial results for the third quarter of 2021. Key Programs' Updates:  Anti-integrin monoclonal antibody program targeting solid tumors continues to advance toward the clinic with first patient dosed antic..."
09/28/2021 8-K Quarterly results
08/18/2021 8-K Quarterly results
08/12/2021 8-K Quarterly results
07/22/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
06/24/2021 8-K Quarterly results
06/17/2021 8-K Quarterly results
06/01/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
03/15/2021 8-K Quarterly results
02/04/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy